StockData
DaVita Inc. logo

DaVita Inc. (DVA) stock analysis

DVANYSEServices-Misc Health & Allied Services, NECFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 13/3041% below fair value
$183.50+4.22 (+2.35%)

Close on Nov 11, 2026Market cap $11.54BP/E 13.5Yield –

StockData Score

Prices as of Nov 11, 2026How the score works

Value5Growth4Performance3Health1Dividend0

Mixed13 of 30 checks passed

DaVita passes 13 of the 30 checks behind our score; 11 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
5/6
Growth
4/6
Past performance
3/6
Financial health
1/6
Dividend
0/6

What stands out

  • Margin of safety over 20%

    The price is 41.2% below fair value, more than the 20% cushion we look for.

  • Trading below fair value

    The share price of $183.50 is below our fair value estimate of $312.00.

  • Return on capital over 10%

    Return on invested capital was 18.1%, above the 10% that usually covers the cost of capital.

  • EPS growing 10%+ a year

    Diluted EPS grew 18.9% a year over the last three fiscal years.

What to watch

  • Earnings shrank over 5 years

    Net income shrank 0.7% a year on average over the last five fiscal years.

  • Revenue growing under 10% a year

    Revenue grew 5.5% a year over the last three fiscal years, short of the 10% we look for.

  • Debt not well covered by cash flow

    Operating cash flow over the last twelve months equals 17.4% of total debt; we look for at least 20%.

  • Elevated bankruptcy risk

    The Altman Z-score is 1.71; above 3 is the safe zone and below 1.8 the distress zone.

Valuation5/6
  • P/E below its 5-year median

    DaVita's P/E of 13.5 is below its own 5-year median of 14.7.

  • P/E below the industry

    DaVita's P/E of 13.5 is below the Health Services median of 23.9.

  • EV/EBITDA above its 5-year median

    DaVita's EV/EBITDA of 7.8 is above its 5-year median of 7.8.

  • P/S below the industry

    DaVita's price-to-sales of 0.81 is below the Health Services median of 1.33 (book value is negative, so we use sales).

  • Trading below fair value

    The share price of $183.50 is below our fair value estimate of $312.00.

  • Margin of safety over 20%

    The price is 41.2% below fair value, more than the 20% cushion we look for.

Growth4/6
  • Revenue growing under 10% a year

    Revenue grew 5.5% a year over the last three fiscal years, short of the 10% we look for.

  • EPS growing 10%+ a year

    Diluted EPS grew 18.9% a year over the last three fiscal years.

  • Earnings growth accelerating

    Net income grew 19.2% over the last twelve months, against a 5-year average of -0.7% a year.

  • Growing faster than the industry

    Revenue grew 6.4% over the last twelve months; the Health Services median is 2.0%.

  • Guidance raised

    DaVita raised its Current 2026 guidance Adjusted operating income outlook on May 5, 2026.

  • Gross margin trend

    This company does not report gross profit.

Past performance3/6
  • Return on equity

    Needs positive equity and five years of results.

  • Return on capital over 10%

    Return on invested capital was 18.1%, above the 10% that usually covers the cost of capital.

  • Return on equity against the industry

    Needs positive equity.

  • Earnings shrank over 5 years

    Net income shrank 0.7% a year on average over the last five fiscal years.

  • Net margin above its 5-year average

    Net margin was 6.5% over the last twelve months, against a 5-year average of 6.3%.

  • Net margin above the industry

    DaVita's net margin of 6.5% is above the Health Services median of -1.0%.

Financial health1/6
  • Debt level

    Needs debt and equity figures.

  • Debt trend

    Needs a balance sheet from five years ago with positive equity.

  • Debt not well covered by cash flow

    Operating cash flow over the last twelve months equals 17.4% of total debt; we look for at least 20%.

  • Interest coverage

    Interest expense is not reported separately.

  • Short-term assets cover short-term debts

    Current assets are 1.41 times current liabilities.

  • Elevated bankruptcy risk

    The Altman Z-score is 1.71; above 3 is the safe zone and below 1.8 the distress zone.

Dividend0/6
  • No dividend

    DaVita has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Our estimate per share

$312.00

The share price is 41% below this estimate.

20%+ below
Near fair value
20%+ above
$183.50Price$312.00Fair value
MethodMultiple usedOwn 5Y medianIndustry medianValue per shareWeight
P/E19.3×14.7×23.9×$261.6144%
EV/EBITDA11.9×7.8×16.2×$371.9439%
Earnings power7.4% cost of equity––$306.5017%
Fair value$312.00100%

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/E at month end
  • Own 5-year median 14.7
  • Health Services median 23.9

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

Low risk

Average value traded per day
$140.52M
Value traded per 1% price move
$79.33M

Downside

High risk

Typical loss in a bad month
25.1%
Volatility (annualized)
47%
Sharpe ratio, 1 year
1.03
Beta to the S&P 500 (5Y)
0.37

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2011 to 2025

Operating margin

15.0%+0.3 pts over 5 years

Net margin

5.5%−1.2 pts over 5 years

See a number that looks wrong?